DelveInsight’s “Cytokine Release Syndrome Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Cytokine Release Syndrome market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Cytokine Release Syndrome market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Cytokine Release Syndrome: An Overview
Cytokine release syndrome (CRS) is a systemic inflammatory response with the outpouring of the inflammatory cytokines due to stimulus triggered by a variety of factors such as infections, and immunotherapy, especially those involving T-cell engagers and certain other drugs. Even though cytokines act to direct immune response, the higher levels of cytokines with increased inflammation can be harmful as they interfere with a number of body functions. In severe cases, CRS can cause organ failure in heart, lung, kidney, liver, and brain function that may even lead to death.
The main cytokines implicated in the pathogenesis of CRS include interleukin-6 (IL-6), IL-10, tumor necrosis factor (TNF), IL-1, IL-2, IL-8, interferon (IFN)-γ, monocyte chemoattractant protein 1 (MCP-1) and granulocyte-macrophage colony-stimulating factor (GM-CSF) and others. CRS clinically manifests when large numbers of lymphocytes (B cells, T cells, and/or natural killer cells) and/or myeloid cells (macrophages, dendritic cells, and monocytes) become activated and release inflammatory cytokines.
Cytokine Release Syndrome Market Key Facts
In 2021, the total Cytokine Release Syndrome market size was USD 4.3 million, which is expected to rise during the study period (2019–2032).
The total Cytokine Release Syndrome market size in the United States accounted for USD 3.5 million in 2021.
In the EU5, the total Cytokine Release Syndrome market size was USD 0.8 million in 2021.
Companies all over the globe are persistently working towards the development of new treatment therapies and some of the key players at the global level are Incyte Corporation, Gilead Company, and others.
In the year 2021, the total number of incident cases of cytokine release syndrome were 48,853 in the 7MM.
According to the DelveInsight, in the year 2021, the total incident cases of cytokine release syndrome were 11,559 in the United States which is expected to grow during the study period, i.e., 2019–2032.
The highest number of total incident cases of cytokine release syndrome was observed in Germany among the EU5 countries with 8,222 cases in 2021.
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Cytokine Release Syndrome market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Cytokine Release Syndrome market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Cytokine Release Syndrome Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Cytokine Release Syndrome Epidemiology, Segmented as –
Incident cases of Cytokine Release Syndrome (CRS) in 7MM [2019–2032]
Age-specific cases of Cytokine Release Syndrome (CRS) [2019–2032]
Incident cases of Severe Cytokine Release Syndrome (CRS) in 7MM [2019–2032]
Incident cases of Hematologic malignancies in 7MM [2019–2032]
Cytokine Release Syndrome Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Cytokine Release Syndrome market or expected to be launched during the study period. The analysis covers the Cytokine Release Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Cytokine Release Syndrome pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Cytokine Release Syndrome Market Will Evolve and Grow by 2032 @
Cytokine Release Syndrome Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Cytokine Release Syndrome. Currently, Novartis is leading the therapeutics market with its Cytokine Release Syndrome drug candidates in the most advanced stage of clinical development.
The Leading Players in the Cytokine Release Syndrome Therapeutics Market Include:
Olatec Therapeutics LLC
Swedish Orphan Biovitrum (sobi)
And Many Others
Cytokine Release Syndrome Emerging and Marketed Drugs Covered in the Report Include:
Itacitinib: Incyte Corporation
Dapansutrile: Olatec Therapeutics LLC
Anakinra& Axicabtagene Ciloleucela: Kite, A Gilead Company
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Cytokine Release Syndrome Competitive Intelligence Analysis
4. Cytokine Release Syndrome Market Overview at a Glance
5. Cytokine Release Syndrome Disease Background and Overview
6. Cytokine Release Syndrome Patient Journey
7. Cytokine Release Syndrome Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Cytokine Release Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Cytokine Release Syndrome Unmet Needs
10. Key Endpoints of Cytokine Release Syndrome Treatment
11. Cytokine Release Syndrome Marketed Products
12. Cytokine Release Syndrome Emerging Drugs and Latest Therapeutic Advances
13. Cytokine Release Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Cytokine Release Syndrome Market Outlook (In US, EU5, and Japan)
16. Cytokine Release Syndrome Access and Reimbursement Overview
17. KOL Views on the Cytokine Release Syndrome Market
18. Cytokine Release Syndrome Market Drivers
19. Cytokine Release Syndrome Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving pharmaceutical market today @ Pharmaceutical Partner Identification Services
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States